Literature DB >> 10809812

A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor.

K Oka1, E Imai, T Moriyama, Y Akagi, A Ando, M Hori, A Okuyama, K Toki, M Kyo, Y Kokado, S Takahara.   

Abstract

BACKGROUND: Prolonging the survival of transplant kidneys is a major task of modern nephrology. It has recently been shown that deteriorating renal function and substantial graft loss were observed in 55% of renal allograft recipients with recurrent IgA nephropathy (IgAN) at long-term follow-up. To gain a useful insight into the therapeutic approach towards protecting allograft kidneys from deteriorating graft function, we compared the histological characteristics of post-transplant IgAN to primary IgAN and investigated the effects of an ACE inhibitor.
METHODS: Twenty-one patients with post-transplant IgAN and 63 patients with primary IgAN were included in the histopathological study. The effectiveness of angiotensin-converting enzyme (ACE) inhibitor treatment in post-transplant IgAN was also studied in 10 patients.
RESULTS: The prevalence of glomeruli with adhesions and/or cellular crescents in primary IgAN was significantly greater than in post-transplant IgAN (P<0.05), but the proportion of glomeruli with segmental sclerosis was similar in both groups. The rate of global obsolescence, and the degree of interstitial fibrosis in post-transplant IgAN were significantly greater than in primary IgAN (P<0.05). The degree of glomerular obsolescence and the severity of interstitial fibrosis correlated with the severity of glomerular lesion in primary IgAN, but not in post-transplant IgAN. In primary IgAN, glomerular diameter significantly correlated with the proportions of glomerular obsolescence, but not in post-transplant IgAN, suggesting that allograft kidneys may be in a hyperfiltration state. Both the blood pressure and the urinary protein excretion significantly improved after ACE-inhibitor treatment (P<0.001).
CONCLUSION: In post-transplant IgAN, histopathological lesions indicative of acute inflammatory insults were suppressed, and glomerular hypertrophy, which may relate to haemodynamic burden such as hyperfiltration, was prominent. Preliminary study of ACE-inhibitor treatment in 10 patients showed favourable effects. A future long-term follow-up study is required to establish the effectiveness of ACE inhibitors in treatment of post-transplant IgAN.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10809812     DOI: 10.1093/ndt/15.5.689

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

1.  Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.

Authors:  Laureline Berthelot; Thomas Robert; Vincent Vuiblet; Thierry Tabary; Antoine Braconnier; Moustapha Dramé; Olivier Toupance; Philippe Rieu; Renato C Monteiro; Fatouma Touré
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

Review 2.  Pathology of IgA nephropathy.

Authors:  Ian S D Roberts
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

3.  Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation.

Authors:  Maria Messina; Maria Cristina di Vico; Claudia Ariaudo; Gianna Mazzucco; Fabrizio Fop; Giuseppe Paolo Segoloni; Luigi Biancone
Journal:  J Nephrol       Date:  2016-05-23       Impact factor: 3.902

4.  Henoch-Schönlein purpura in a renal transplant recipient with prior IgA nephropathy following influenza vaccination.

Authors:  Andrew McNally; David McGregor; Martin Searle; John Irvine; Nicholas Cross
Journal:  Clin Kidney J       Date:  2013-04-11

Review 5.  Recurrence of primary glomerulonephritis: Review of the current evidence.

Authors:  Fedaey Abbas; Mohsen El Kossi; Jon Kim Jin; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2017-12-24

6.  Clinical Features, Treatment and Prognostic Factors of Post-Transplant Immunoglobulin A Nephropathy.

Authors:  Diogo Buarque Cordeiro Cabral; Tainá Veras de Sandes-Freitas; José Osmar Medina-Pestana; Gianna Mastroianni-Kirsztajn
Journal:  Ann Transplant       Date:  2018-03-09       Impact factor: 1.530

Review 7.  Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation.

Authors:  Gabriella Moroni; Mirco Belingheri; Giulia Frontini; Francesco Tamborini; Piergiorgio Messa
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

8.  Possible beneficial association between renin-angiotensin-aldosterone-system blockade usage and graft prognosis in allograft IgA nephropathy: a retrospective cohort study.

Authors:  Sehoon Park; Chung Hee Baek; Heounjeong Go; Young Hoon Kim; Sang-Il Min; Jongwon Ha; Yong Chul Kim; Jung Pyo Lee; Yon Su Kim; Kyung Chul Moon; Su-Kil Park; Hajeong Lee
Journal:  BMC Nephrol       Date:  2019-09-11       Impact factor: 2.388

Review 9.  Recurrent Glomerulonephritis after Renal Transplantation: The Clinical Problem.

Authors:  Barbara Infante; Michele Rossini; Serena Leo; Dario Troise; Giuseppe Stefano Netti; Elena Ranieri; Loreto Gesualdo; Giuseppe Castellano; Giovanni Stallone
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

10.  Outcome of glomerulonephritis in live-donor renal transplant recipients: A single-centre experience.

Authors:  Ahmed Ibrahim Akl; Hany Adel; Mona Abdel Rahim; Ehab Wahba Wafa; Ahmed A Shokeir
Journal:  Arab J Urol       Date:  2015-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.